Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

3.82
-0.0500-1.29%
Post-market: 3.820.00000.00%16:10 EST
Volume:101.12K
Turnover:396.55K
Market Cap:25.81M
PE:-0.70
High:4.10
Open:3.89
Low:3.82
Close:3.87
52wk High:6.01
52wk Low:3.20
Shares:6.76M
Float Shares:5.60M
Volume Ratio:0.56
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4689
EPS(LYR):-10.1953
ROE:-275.85%
ROA:-106.65%
PB:7.43
PE(LYR):-0.37

Loading ...

BRIEF- Shane Schaffer Reinstated As CEO Of Cingulate

Reuters
·
Dec 16

Cingulate Inc - Shane Schaffer Reinstated as CEO of Cingulate - SEC Filing

THOMSON REUTERS
·
Dec 15

Cingulate Inc: John Roberts Will No Longer Serve as Exec Chairman but Will Continue to Serve as Chairman of Board

THOMSON REUTERS
·
Dec 15

Cingulate Inc. Revises CEO Compensation Terms Following Administrative Leave

Reuters
·
Dec 15

Cingulate Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 08

Cingulate Is Maintained at Buy by Roth Capital

Dow Jones
·
Nov 20

Cingulate price target lowered to $16 from $17 at Roth Capital

TIPRANKS
·
Nov 19

Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences

Reuters
·
Nov 19

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17

Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

TIPRANKS
·
Nov 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

TIPRANKS
·
Nov 13

Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations

Reuters
·
Nov 13

Cingulate Inc. posts third quarter loss of $6.0 million

Reuters
·
Nov 13

Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey

Reuters
·
Nov 11

Cingulate Inc. Appoints Bryan Downey as Chief Commercial Officer

Reuters
·
Nov 10

Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Dow Jones
·
Nov 10

BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301

Reuters
·
Oct 28

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

GlobeNewswire
·
Oct 28

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

GlobeNewswire
·
Oct 24